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phenotypic data across the neurological disease spectrum 
to reﬁne, replicate, and expand these ﬁndings.
Genetic modiﬁers of multiple sclerosis progression, 
severity, and onset
Between 30 and 50% of MS risk is genetic, but there has 
been limited progress in identifying genetic variants that 
aﬀect disease severity or outcome. In this month’s ﬁrst 
paper, Sadnovick et al. report results of an ‘extremes of out-
come’ analysis of 2016 patients with MS to identify genetic 
variants that inﬂuence age at onset (AAO) and rate of dis-
ability accumulation. Fifty patients at each end of the disa-
bility spectrum underwent exome sequencing. This approach 
detected 38 missense or nonsense variants with nominally 
signiﬁcant diﬀerence in frequency between the groups.
The 38 identiﬁed variants were genotyped in the remain-
der of the cohort to seek correlation with severity, clini-
cal course, and AAO. The multiple sclerosis severity score 
(MSSS) was calculated for each patient from a single EDSS 
measurement and was used in a linear regression model 
adjusted for sex and AAO. Two variants were found to have 
nominal signiﬁcance: one in the gene PSMG4 and one in 
NLRP5. Variants in these two genes also correlated with 
earlier AAO, while a variant in MC1R appeared to delay 
onset by nearly 2 years. Clinical course was correlated with 
a variant in EIF2AK1, which was associated with a 50% 
greater risk of primary-progressive MS relative to relapsing-
onset MS.
Of the genes identiﬁed, PSMG4 and MC1R are perhaps 
the most interesting. PSMG4 encodes a chaperone protein 
involved in assembling the 26S proteasome, a major pro-
tein disposal pathway. Reduced activity of the 26S protea-
some has been shown to cause neuronal death by impaired 
Introduction
Genome-wide association studies (GWAS) now available 
for many common neurological disorders have been highly 
informative, for example, identifying more than 110 rep-
licated genetic variants associated with multiple sclerosis 
(MS). However, there has been relatively limited progress in 
identifying genetic modiﬁers of disease severity and clinical 
phenotypes. This has now become an area of active research, 
since it oﬀers a substantial opportunity to detect both prog-
nostic biomarkers and novel therapeutic targets. Classical 
GWAS is a simple comparison of genotypes between cases 
and controls, but measuring disease severity is more com-
plex and leads to substantial variation in methodology. A 
fundamental limiting factor to date has been the lack of large 
cohorts with detailed long-term clinical data that allow pow-
erful and meaningful correlations to be drawn. However, 
recent work in three neurological disorders has been able 
to successfully overcome these historical limitations and 
have identiﬁed genetic variants that correlate with clinical 
outcome.
This month’s journal club discusses four recent papers 
that have used diﬀerent approaches to identify genetic modi-
ﬁers of clinical severity and phenotypes in MS, Alzheimer’s 
disease (AD), and Huntington’s disease (HD). With these 
methodological advances comes a need for even larger 
cohorts of genotyped patients with detailed longitudinal 
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degradation of abnormal proteins. The 26S proteasome has 
also been shown to hydrolyse myelin basic protein to pro-
duce antigenic peptides for presentation to T cells. MC1R
encodes the receptor for melanocyte-stimulating hormone 
and the identiﬁed variant is associated with the phenotype 
of red hair, pale skin, and freckles. This phenotype facili-
tates synthesis of vitamin D in low UV light environments 
and so may confer protection through vitamin D-related 
mechanisms.
Comment. Exome sequencing in patients at the extremes 
of outcome maximises power to discover high impact 
variants. Several genes were identiﬁed, but none survived 
experiment-wide correction for multiple comparisons 
and there was no adjustment for treatment, so replication 
will be imperative before ﬁrm conclusions can be drawn. 
Exome sequencing restricts analysis to the coding genome, 
so future work should extend to the non-coding genome, 
because genetic modiﬁers of MS severity may lie in regula-
tory regions. Finally, using the MSSS as a severity meas-
ure is problematic for several reasons. First, it has not been 
validated longitudinally against long-term disability data 
and so may not be a stable measure of long-term outcome. 
Second, it relies on a single EDSS measurement, which is 
highly operator-dependent and prone to inaccuracy. Third, 
the distribution of MSSS data is highly variable, so linear 
regression may not be applicable. Future work should con-
sider survival analysis of long-term disability data to pro-
duce reliable, sensitive, and clinically meaningful results.
Sadnovick AD et al (2017) Clin Immunol 180:100–105.
Gene variants of adhesion molecules act 
as modiﬁers of disease severity in MS
A second method to identify novel treatment targets is to 
restrict analysis to genes involved in modiﬁable pathways. 
Dardiotis et al. genotyped 147 single nucleotide polymor-
phisms (SNPs) in nine genes involved in trafficking of 
lymphocytes into the central nervous system (CNS) in 389 
Greek patients with MS. They performed linear regression 
for AAO and MSSS, adjusting for sex and study site in the 
former and treatment (cumulative duration) and AAO in the 
latter, with signiﬁcance determined by permutation. One 
variant in gene FN1 was found to associate with AAO and 
two variants were found to associate with MSSS: one in gene 
ITGA4 and one in gene SPP1, with each SNP exhibiting an 
allelic dosing eﬀect.
Comment. While the sensitivity of this work may have 
been limited by the deﬁciencies of the MSSS, this paper 
suggests that mechanisms regulating lymphocyte traﬃcking 
into the CNS are important in determining MS severity. Tar-
geted analysis of selected genes with known functions can 
yield important information about disease mechanisms. One 
of the genes identiﬁed in this study is the molecular target 
of natalizumab, a potent disease-modifying drug for MS, 
illustrating the potential of such an approach for identifying 
novel therapeutics.
Dardiotis E et al (2017) Neurol Neuroimmunol Neuroin-
ﬂam 4(4):e350.
Identiﬁcation of genetic variants associated 
with Huntington’s disease progression: 
a genome-wide association study
Monogenic disorders, such as HD, provide a powerful model 
for detection of genetic modiﬁers of disease outcomes. In 
this study, Moss et al. show how highly detailed longitudi-
nal clinical data from a modest cohort can lead to success-
ful detection of genetic modiﬁers of disease severity on a 
genome-wide scale.
TRACK-HD is a prospective observational study of 216 
patients with HD with highly detailed clinical and brain 
volume MRI data over 3 years. Progression slopes for out-
come measures that were correlated with each other and 
independent of CAG repeat length and age were included 
in a principal component analysis to produce a TRACK-HD 
progression score. Genome-wide chip-based SNP genotyp-
ing was performed and a mixed linear regression model 
applied, treating TRACK-HD progression score as a quan-
titative trait. A locus on chromosome 5 was identiﬁed that 
reached genome-wide signiﬁcance, which spanned three 
genes: DHFR, MSH3, and MTRNR2L2. The ﬁnding was 
replicated by analysis 1773 individuals from REGISTRY, 
a multicentre, prospective, observational study of patients 
with HD. Despite REGISTRY data having fewer measure-
ments, signiﬁcant missing data, and no imaging, genome-
wide association analysis of the ﬁrst principal component of 
the most recent data identiﬁed the same locus on chromo-
some 5.
The index SNP is a coding missense variant in MSH3. 
MSH3 encodes a neuronally expressed DNA mismatch 
repair protein, which has been implicated in HD pathol-
ogy in mouse and in vitro studies. DNA repair pathways 
were also signiﬁcantly associated with progression and 
gene expression analysis showed that reduced expression 
of MSH3 was associated with slower disease progression.
Comment. This paper reports a genetic locus that appears 
to modify progression in HD. The ﬁndings support the 
model that somatic expansion of the CAG repeat in HTT is 
a driver of HD progression. The work also shows the utility 
of detailed phenotypic data to reveal genetic modiﬁers of 
severity on a genome-wide scale. Interestingly, despite larger 
numbers, the association was weaker in the REGISTRY, the 
cohort with patchy clinical data. Combining detailed clinical 
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data across multiple modalities may produce important 
insights in other neurological disorders.
Moss DJH et al (2017) Lancet Neurol.
Genome-wide association study identiﬁes 
four novel loci associated with Alzheimer’s 
endophenotypes and disease modiﬁers
The ﬁnal paper discussed that this month illustrates the 
power of using endophenotypes to identify genetic asso-
ciations with disease risk and severity. Endophenotypes are 
measurable traits that strongly associate with a disorder and 
share its genetic architecture. Endophenotypes can, there-
fore, be used as quantitative surrogate markers of disease. 
This allows greater sensitivity for detecting genetic risk vari-
ants in smaller sample sizes, but also provides mechanistic 
information linking genotype to disease. Deming et al. per-
formed extensive analysis of 3146 patients with AD from 
nine studies, utilising well-established endophenotypes of 
AD: cerebrospinal ﬂuid (CSF) levels of amyloid-β (Aβ), tau, 
and phosphorylated tau (ptau).
All patients underwent chip-based SNP genotyping. 
After normalising CSF measurements across diﬀerent sites, 
a combined GWAS was performed applying linear regres-
sion of each SNP on CSF Aβ, tau, and ptau levels, adjusted 
for study, age, and sex. In addition to replicating previously 
associated loci, they identiﬁed two novel associations with 
ptau and Aβ: a variant on chromosome 13 near PCDH8 and 
one on chromosome 18 near CTDP1. Aβ was also associated 
with two further novel variants: one on chromosome 1 near 
GLIS1 and one on chromosome 6 within SERPINB1. Further 
analysis suggested that approximately 35.5 and 24.9% of the 
variance in CSF levels of Aβ and ptau, respectively, were 
explained by common genetic variants.
The authors then investigated the genetic overlap between 
variants associated with CSF Aβ, tau and ptau levels, and 
AD risk, age at onset and clinical progression rate in inde-
pendent cohorts. Progression was measured by the annual 
change in Clinical Dementia Rating Sum of Boxes (CDR-
SB) over at least 1.5 years following diagnosis after adjust-
ing for age, sex, baseline CDR-SB, follow-up time, level 
of education, and site. The novel variants associated with 
Aβ (GLIS1 and SERPINB1) were also associated with AD 
risk, AAO and progression, and previously reported variants 
associated with tau and ptau also associated with AD risk 
and AAO.
Comment. This is an extensive paper, but the key ﬁnd-
ings establish genetic variants that associate with CSF lev-
els of Aβ, tau, and ptau, which also correlate with AD risk, 
AAO, and rate of progression. This reinforces the potential 
of these CSF proteins as biomarkers of prognosis, as well 
as diagnosis and illustrates how endophenotypes can be 
used to identify informative genes despite modest sample 
size.
Deming Y et al (2017) Acta Neuropathol 133(5):839–856.
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